Skip to main content

Advertisement

SpringerLink
Log in

Baseline serum glucose concentration and symptomatic haemorrhagic transformation in non-diabetic stroke patients treated by intravenous thrombolysis

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Intravenous (i.v.) recombinant tissue plasminogen activator (rt-PA) improves outcome in ischaemic stroke, despite an increased risk of symptomatic haemorrhagic transformation (sHT). A higher baseline serum glucose concentration is associated with an increased risk of sHT. However, as most studies did not exclude diabetic patients, this effect may be partially due to diabetic micro-angiopathy. Our objective was to test the hypothesis that baseline serum glucose concentration is associated with sHT in non-diabetic patients treated by i.v. rt-PA. We analysed the influence of baseline serum glucose concentrations on sHT (ECASS2 definition) in consecutive non-diabetic patients treated by i.v. rt-PA for ischaemic stroke. Secondary end-points were death (<7 days, 8 days to 3 months, all deaths <3 months), and unfavourable outcome at 3 months (modified Rankin scale 2–6 if different from the pre-stroke value). Five hundred and five consecutive patients met inclusion criteria [242 men (47.9 %); median age 71 years (interquartile range, IQR) 57–81; median baseline national institutes of health stroke scale score 12 (IQR 6–17)]. Thirty-seven had sHT (7.3 %). After adjustment, baseline serum glucose concentrations were independently associated with sHT (adjOR: 1.176 for 1 mmol/l increase; 95 % CI: 1.020–1.357: p = 0.025). Increased admission serum glucose concentrations in non-diabetic patients treated by i.v. rt-PA for cerebral ischaemia are associated with sHT. Whether lowering serum glucose lowers the risk of sHT needs to be evaluated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19(5):604–607

    Article  PubMed  Google Scholar 

  2. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 333:1581–1587

    Article  Google Scholar 

  3. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359(13):1317–1329

    Article  PubMed  CAS  Google Scholar 

  4. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S (2004) Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363(9411):768–774

    Article  PubMed  Google Scholar 

  5. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, Butcher KS, Parsons MW, Barber PA, Levi C, Bladin C, Byrnes G (2010) Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 375(9727):1695–1703

    Article  PubMed  CAS  Google Scholar 

  6. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G (2007) Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study. Lancet 369(9558):275–282

    Article  PubMed  CAS  Google Scholar 

  7. Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, Roine RO, Toni D, Lees KR (2008) Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 372(9646):1303–1309

    Article  PubMed  CAS  Google Scholar 

  8. Dungan KM, Braithwaite SS, Preiser JC (2009) Stress hyperglycaemia. Lancet 373(9677):1798–1807

    Article  PubMed  CAS  Google Scholar 

  9. Ste-Marie L, Hazell AS, Bemeur C, Butterworth R, Montgomery J (2001) Immunohistochemical detection of inducible nitric oxide synthase, nitrotyrosine and manganese superoxide dismutase following hyperglycemic focal cerebral ischemia. Brain Res 918(1–2):10–19

    Article  PubMed  CAS  Google Scholar 

  10. Desilles JP, Meseguer E, Labreuche J, Lapergue B, Sirimarco G, Gonzalez-Valcarcel J, Lavallee P, Cabrejo L, Guidoux C, Klein I, Amarenco P, Mazighi M (2013) Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: a registry and systematic review. Stroke 44(7):1915–1923

    Article  PubMed  CAS  Google Scholar 

  11. Mazighi M, Amarenco P (2001) Hyperglycémie: un facteur de mauvais pronostic a la phase aiguë de l’AVC. Diabetes Metab 27(6):718–720

    PubMed  CAS  Google Scholar 

  12. The European Stroke Organisation (ESO) executive committee (2008) Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25(5):457–507. http://www.eso-stroke.org/pdf/ESO%420Guidelines_update_Jan_2009.pdf

  13. Rocco A, Heuschmann PU, Schellinger PD, Kohrmann M, Diedler J, Sykora M, Nolte CH, Ringleb P, Hacke W, Juttler E (2013) Glycosylated hemoglobin A1 predicts risk for symptomatic hemorrhage after thrombolysis for acute stroke. Stroke 44(8):2134–2138

    Article  PubMed  CAS  Google Scholar 

  14. Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lanari A, Caso V, Micheli S, Bertolani L, Venti M, Palmerini F, Biagini S, Comi G, Previdi P, Silvestrelli G (2008) Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke 39(8):2249–2256

    Article  PubMed  Google Scholar 

  15. Toyoda K, Koga M, Naganuma M, Shiokawa Y, Nakagawara J, Furui E, Kimura K, Yamagami H, Okada Y, Hasegawa Y, Kario K, Okuda S, Nishiyama K, Minematsu K (2009) Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. Stroke 40(11):3591–3595

    Article  PubMed  CAS  Google Scholar 

  16. Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M, Levine SR (2002) Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 105(14):1679–1685

    Article  PubMed  CAS  Google Scholar 

  17. Fluri F, Hatz F, Rutgers MP, Georgiadis D, Sekoranja L, Schwegler G, Sarikaya H, Weder B, Muller F, Luthy R, Arnold M, Reichhart M, Mattle HP, Tettenborn B, Nedeltchev K, Hungerbuhler HJ, Sztajzel R, Baumgartner RW, Michel P, Lyrer PA, Engelter ST (2010) Intravenous thrombolysis in patients with stroke attributable to small artery occlusion. Eur J Neurol 17(8):1054–1060

    Article  PubMed  CAS  Google Scholar 

  18. Cordonnier C, Girot M, Dorp E, Rimetz P, Bouillaguet S, Henon H, Lucas C, Godefroy O, Leys D (2000) Stroke units from scientific evidence to practice: the experience of the Lille stroke unit. Cerebrovasc Dis 10(Suppl 4):17–20

    Article  PubMed  Google Scholar 

  19. Bodenant M, Leys D, Debette S, Cordonnier C, Dumont F, Henon H, Girot M, Lucas C, Devos D, Defebvre L, Deplanque D, Leclerc X, Bordet R (2010) Intravenous thrombolysis for acute cerebral ischaemia: comparison of outcomes between patients treated at working versus nonworking hours. Cerebrovasc Dis 30(2):148–156

    Article  PubMed  Google Scholar 

  20. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH et al (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 274(13):1017–1025

    Article  PubMed  CAS  Google Scholar 

  21. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Scheider D, Diez-Tejedor E, Trouilas P (1998) Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 352:1245–1251

    Article  PubMed  CAS  Google Scholar 

  22. Strbian D, Sairanen T, Meretoja A, Pitkaniemi J, Putaala J, Salonen O, Silvennoinen H, Kaste M, Tatlisumak T (2011) Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology 77(4):341–348

    Article  PubMed  CAS  Google Scholar 

  23. Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Haley EC, Grotta J, Marler J (1994) Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 25(11):2220–2226

    Article  PubMed  CAS  Google Scholar 

  24. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial TOAST Trial of Org 10172 in Acute Stroke Treatment. Stroke 24(1):35–41

    Article  PubMed  Google Scholar 

  25. Bendel R, Afifi A (1977) Comparison of stopping rules in forward regression. J Am Stat Ass 72:46–53

    Google Scholar 

  26. Glantz S, Slinker B (1990) Primer of applied regression and analysis of variance. McGraw Hill, New York

    Google Scholar 

  27. Arnold M, Mattle S, Galimanis A, Kappeler L, Fischer U, Jung S, Demarchis G, Gralla J, Mono ML, Brekenfeld C, Meier N, Nedeltchev K, Schroth G, Mattle HP (2012) Impact of admission glucose and diabetes on recanalization and outcome after intra-arterial thrombolysis for ischaemic stroke. Int J Stroke. doi:10.1111/j.1747-4949.2012.00879.x

    Google Scholar 

  28. Caso V, Paciaroni M, Venti M, Palmerini F, Silvestrelli G, Milia P, Biagini S, Agnelli G (2007) Determinants of outcome in patients eligible for thrombolysis for ischemic stroke. Vasc Health Risk Manag 3(5):749–754

    PubMed  Google Scholar 

  29. Poppe AY, Majumdar SR, Jeerakathil T, Ghali W, Buchan AM, Hill MD (2009) Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis. Diabetes Care 32(4):617–622

    Article  PubMed  Google Scholar 

  30. Ahmed N, Davalos A, Eriksson N, Ford GA, Glahn J, Hennerici M, Mikulik R, Kaste M, Lees KR, Lindsberg PJ, Toni D (2010) Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR). Arch Neurol 67(9):1123–1130

    Article  PubMed  Google Scholar 

  31. Meurer WJ, Scott PA, Caveney AF, Majersik JJ, Frederiksen SM, Sandretto A, Holden AB, Silbergleit R (2010) Lack of association between hyperglycaemia at arrival and clinical outcomes in acute stroke patients treated with tissue plasminogen activator. Int J Stroke 5(3):163–166

    Article  PubMed  Google Scholar 

  32. Fan X, Ning M, Lo EH, Wang X (2013) Early insulin glycemic control combined with tPA thrombolysis reduces acute brain tissue damages in a focal embolic stroke model of diabetic rats. Stroke 44(1):255–259

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We are grateful to Anne-Marie Bordet who contributed to the data collection.

Conflicts of interest

Didier Leys, Hilde Hénon, and Charlotte Cordonnier have been investigators for the ECASS3 trial. The other authors declare no disclosure in relation with this manuscript.

Author information

Authors and Affiliations

  1. UDSL, EA 1046, University Lille Nord de France, 59000, Lille, France

    Mayi Gnofam, Didier Leys, Nelly Ponchelle-Dequatre, Marie Bodenant, Hilde Hénon, Régis Bordet & Charlotte Cordonnier

  2. Stroke Unit, Department of Neurology, CHU Lille, Roger Salengro Hospital, rue Emile Laine, 59037, Lille, France

    Didier Leys, Nelly Ponchelle-Dequatre, Marie Bodenant, Hilde Hénon & Charlotte Cordonnier

  3. Department of Pharmacology, CHU Lille, Lille, France

    Régis Bordet

Authors
  1. Mayi Gnofam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Didier Leys
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nelly Ponchelle-Dequatre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marie Bodenant
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hilde Hénon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Régis Bordet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Charlotte Cordonnier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Didier Leys.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gnofam, M., Leys, D., Ponchelle-Dequatre, N. et al. Baseline serum glucose concentration and symptomatic haemorrhagic transformation in non-diabetic stroke patients treated by intravenous thrombolysis. J Neurol 260, 2786–2792 (2013). https://doi.org/10.1007/s00415-013-7069-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-013-7069-x

Keywords

Search

Navigation